Full title: Challenges in Clinical Diagnosis of Clade I Mpox: Highlighting the Need for Enhanced

**Diagnostic Approaches** 

Short title: Challenges in Clinical Diagnosis of Clade I Mpox

Authors: Josephine Bourner<sup>1</sup>, Esteban Garcia<sup>1</sup>, Festus Mbrenga<sup>2</sup>, Yap Boum II<sup>2</sup>, Amy Paterson<sup>1</sup>,

Benjamin Jones<sup>1</sup>, Piero Olliaro<sup>1</sup>, Emmanuel Nakouné<sup>2</sup>, Amanda Rojek<sup>1</sup>

Affiliations:

<sup>1</sup> ISARIC, Pandemic Sciences Institute, University of Oxford, Oxford, UK

<sup>2</sup> Institut Pasteur de Bangui, Bangui, Central African Republic

Corresponding author : josephine.bourner@ndm.ox.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### Abstract

**Background**: Due to limited diagnostic capacity and availability of point-of-care tests, diagnosis of Clade I mpox in the regions most affected by the disease is usually on clinical grounds and may be complicated due to the similarity between mpox and varicella (chickenpox) lesions. Clinical assessment of lesions is also used for determining clinical progress and has been used to assess patient outcomes in clinical trials. However, there has been no investigation into whether clinicians can (i) identify Clade I mpox compared to other viral lesions (ii) differentiate between Clade I mpox lesion stages.

**Methodology/Principle findings**: The objective of this study was to evaluate inter-rater reliability and agreement between clinicians assessing lesions in patients with Clade I mpox. We presented clinicians with 17 images of Clade I mpox or varicella and asked them to independently indicate the most likely diagnosis – mpox or varicella – and to categorise the lesions according to their stage. When selecting the most likely diagnosis, accuracy varied across all images, the inter-rater reliability was poor ( $\kappa = 0.223$ ; z = 10.1) and agreement was moderate ( $P_o = 68\%$ ). When categorising lesions according to their type, if a single lesion type was present in the image, inter-rater reliability was moderate ( $\kappa = 0.671$ , z = 40.6) and agreement was good ( $P_o = 78\%$ ), but when multiple lesion types were shown in an image, both inter-rater reliability ( $\kappa = 0.153$ , z = 10.5) and agreement ( $P_o = 29\%$ ) decreased substantially.

**Conclusions**: This study demonstrates that there are presently limitations in using clinical assessment to diagnose Clade I mpox and evaluate lesion stage and treatment outcomes, which have an impact on clinical practice, public health and clinical trials. More robust indicators and tools are required to inform clinical, public-health, and research priorities, but these must be implementable in countries affected by mpox.

## Author summary

Mpox is a zoonotic illness caused by the monkeypox virus (MPXV), for which there are two distinct sub-clades. Clade I is typically found in central Africa and is associated with worse patient outcomes than Clade II. Diagnosis of mpox is most commonly performed using PCR, but in settings with limited laboratory capacity diagnosis is usually performed on clinical grounds taking lesion presentation in to account. Lesion presentation is also used to assess patient outcomes in both clinical and research settings. However, there has been no investigation into whether clinicians can (i) identify Clade I mpox compared to other viral lesions (ii) differentiate between Clade I mpox lesion stages, which has important implications for clinical practice, research and public health. Our study, which presented 16 clinicians with 17 sets of images of Clade I mpox or varicella and asked them to i) provide the most likely diagnosis and ii) categorise the lesions in to their stages, demonstrates that there are presently limitations in using clinical assessment to diagnose Clade I mpox and evaluate lesion stage and treatment outcomes. Alternative methods and tools are therefore required that can be easily implemented in affected countries.

# 1 Introduction

Mpox is a zoonotic illness caused by the monkeypox virus (MPXV), for which there are two distinct
genetic sub-types, referred to as Clades. (1) Clade I mpox is found primarily in central Africa and is
associated with worse patient outcomes than Clade II, which is further divided into Clade IIa
(historically reported in west Africa) and Clade IIb, which caused a Public Health Emergency of
International Concern (PHEIC) in 2022. (1)

7 There is a growing epidemic of Clade I mpox in the Democratic Republic of the Congo (DRC) – with a 8 doubling in the number of cases over last year's. (2) There are several concerning features to this 9 outbreak, including an expansion in geographical areas affected, new introduction to dense urban 10 populations (including Kinshasa, the capital city of DRC), and the first descriptions of sexual 11 transmission of this clade. Both the World Health Organization (WHO) and European Centre for 12 Disease Prevention and Control risk assessments (ECDC) highlight that improving awareness and 13 support for clinicians to diagnose cases is a key response priority. (2, 3) While Clade II mpox is rarely 14 fatal – 156 death out of over 91,000 cases reported outside Africa since May 2002 – , mortality 15 associated with Clade I mpox is 1-12% (1) and there have been 581 deaths reported out of over 16 12,500 cases in DRC since February 2023. (2)

However, diagnosis of mpox is difficult. Confirmation of mpox diagnosis is primarily by PCR, (4, 5)
but, concerningly, new evidence suggests that the Clade I-specific RT-PCR test recommended by the
US CDC is impacted due to genetic mutations in the virus causing this outbreak. (6) There are no
point-of-care or rapid diagnostic tests alternatives at present. Laboratory diagnosis is impacted by
operational challenges and limited laboratory capacity –in the present DRC epidemic, only 9% of
suspected mpox cases have been tested by PCR. (7)

Therefore, diagnosis of Clade I mpox in the regions most affected is usually on clinical grounds. This
is reported as difficult due to the similarity between mpox and varicella (chickenpox) lesions. Clinical

25 assessment of lesions is also used for determining clinical progress. Whether a lesion is 'active', 26 'inactive' or 'resolved' is used for determination of infectivity and infection-prevention and control 27 requirements, decisions around whether to offer a patient access to potential treatments, and 28 declarations of cure. The assessment of lesions has in addition become the focal area of evaluation 29 in clinical trials. Several trials for Clade I and Clade II mpox use time to lesion resolution as the 30 primary endpoint to indicate treatment success. (8-12) 31 Despite the myriad uses of clinical diagnosis of Clade I mpox, there has been no investigation into 32 whether clinicians can (i) identify Clade I mpox compared to other viral lesions (ii) differentiate

33 between Clade I mpox lesion stages – although some suspected limitations of this endpoint have

34 already been identified. (13) A previous exercise undertaken by these authors on Clade IIb lesions

35 demonstrated only moderate agreement among different assessors. (14)

36 This study evaluates agreement between clinicians on a differential diagnosis between Clade I mpox

37 and varicella, and classification of lesion stages. Whether mpox Clade I lesions can be reliably

38 classified on clinical grounds has important implications both in the low-resource settings where the

39 virus circulates and in the event of spread to historically non-endemic regions – for decisions on

40 treatment, public health control, and for the robustness of clinical research.

### 41 Methods

The objective of this study was to evaluate inter-rater reliability and agreement between clinicians
assessing lesions in patients with Clade I mpox. Two focal areas of agreement and reliability were
evaluated: 1) differential diagnosis between Clade I mpox and varicella based on lesion presentation;
2) categorisation of lesion stages. The design, conduct and results of this study are reported
according to the Guidelines for Reporting Reliability and Agreement Studies (GRAAS). (15) Ethical
approval for this study was obtained from the University of Oxford Medical Science Interdivisional
Research Ethics Committee (R84355/RE001).

#### 49 Participants

- 50 The participants in this study were clinicians who had experience treating and managing patients
- 51 with Clade I mpox.

#### 52 Data collection

- Using the RedCap survey tool (16, 17), participants were shown 17 sets of images of patients with
- 54 either Clade I mpox or varicella lesions confirmed by PCR. The anonymised images selected for use in
- the survey were derived from the Institut Pasteur de Bangui clinical image library and showed
- 56 lesions of different stages and located on different areas of the body.
- 57 Based on the lesion presentation in the images, the participants were asked to independently
- 58 indicate the most likely diagnosis mpox or varicella and to categorise the lesions as being either
- 59 active, scabbed or resolved, or they had the option to state they were unable to classify the lesions.
- 60 Before starting the questionnaire, participants were shown the World Health Organisation's working
- 61 definition of each lesion stage. (18)
- 62 The survey also captured each clinician's country of practice, average number of patients they
- 63 manage with Clade I mpox in a year, and their self-rated confidence evaluating mpox lesions.
- 64 Confidence evaluating mpox lesions was assessed on an ordinal scale from one to ten, with one
- 65 representing no confidence and ten representing complete confidence.
- The questionnaire used in this study can be found in S1 Appendix 1 and was provided in both
  English and French.

#### 68 Data analysis

- 69 All analyses completed in this study were conducted with the 'irr' package in R Statistical Software
- 70 (v4.3.2) (19) and validated using 'statsmodels' package in Python (v3.11.5) by two analysts.
- 71 Accuracy identifying mpox or varicella was evaluated using the percentage of raters selecting the
- 72 correct diagnosis for each image. Spearman's rank correlation coefficient (Spearman's ρ) was

73 employed to assess the relationship between experience—assessed by self-reported expertise and 74 the number of patients managed— and each evaluator's accuracy percentage. Spearman's method, 75 chosen for its suitability with small samples and ordinal data without assuming a normal distribution, 76 necessitates a cautious interpretation of results due to the reduced statistical power and potential 77 influence of noise and outliers inherent to limited datasets. 78 Inter-rater reliability was evaluated using Fleiss' kappa coefficient (k) and inter-rater agreement was 79 evaluated using proportion of partial agreement ( $P_0$ ), and proportion of exact agreement ( $P_{oe}$ ). Partial 80 agreement refers to the agreement between any one of the participants' selections in a multiple-

choice answer and exact agreement refers to a complete match between participants' selections in a
multiple-choice answer.

83 Questions related to lesion classification assessed only the images in which the patient had a

84 confirmed diagnosis of mpox. The first analysis evaluates responses to the images where only a

85 single or homogenous lesions were present and for which the κ and P<sub>oe</sub> are reported. The second

86 analysis evaluates responses to the images where multiple types of lesions (combinations of active,

scabbed and resolved) are present, for which the  $\kappa$ , the P<sub>o</sub> the P<sub>oe</sub> are reported.

#### 88 Results

89 The questionnaire was sent to 38 potential participants in total, of whom 17 accessed the

90 questionnaire and completed the eligibility check. One respondent was not eligible to participate as

91 they were not directly involved in the clinical management of patients with Clade I mpox.

92 All 16 participants who started the questionnaire completed it in full. A summary of the participants'

93 country of work, confidence assessing an mpox lesion and number of mpox patients they have

94 personally managed is summarised in **Table 1**.

95

### 96 **Table 1 – Description of study participants**

Country of work, n (%):				
Democratic Republic of Congo	8 (50%)			
Central African Republic	2 (13%)			
France	2 (13%)			
United Kingdom	2 (13%)			
Nigeria	1 (6%)			
Belgium	1(6%)			
Number of mpox patients the respondents has personally managed, n (%):				
<5	0			
5-10	2 (13%)			
10-20	1 (6%)			
20-50	5 (31%)			
>50	8 (50%)			
Confidence assessing mpox lesions, median (IQR):				
Confidence score	8 (7.5 - 8)			

97

#### 98 Diagnosis

- 99 Accuracy selecting the most likely diagnosis between mpox and varicella based on lesion
- 100 presentation varied across all images, with between 25% and 100% of the respondents correctly
- identifying the disease and a median = 75% (Q1: 62.5%, Q3: 93.75%). No correlation was detected
- between accuracy and either self-rated confidence (Spearman's  $\rho = 0.3$ ) or experience (Spearman's  $\rho$
- 103 = 0.17) assessing lesions (**Table 2**).

#### 104 Table 2 – Correlation between raters' diagnostic accuracy, self-rated confidence and experience

105 using Spearman's correlation (ρ)

	Image	Self-rated confidence	Experience
Image	1	0.3	0.168
Self-rated confidence	0.3	1	-0.042
Experience	0.168	-0.042	1

106

- 107 When asked to select the most likely diagnosis of the patient between varicella and mpox based on
- 108 the lesion presentation shown in the images, the inter-rater reliability was poor ( $\kappa = 0.223$ ; z = 10.1)
- and agreement was moderate ( $P_o = 68\%$ ). (Fig 1)

#### 110 Fig 1. Dendrogram of the suspected diagnosis associated with the images based on lesion

#### 111 presentation

- 112 In addition to the reported results, in the supplementary appendices we show that there appears to
- 113 be improved diagnostic accuracy if a single lesion type is present in the image, compared to images
- in which lesions appeared to be in multiple concurrent stages of evolution (**S2 Appendix 2**). We did
- 115 not observe any relationship between diagnosis and accuracy (S2 Appendix 2). However, our
- sample size is too small to draw any generalisable conclusions.

#### 117 Lesion classification

- 118 When a single lesion type was present in the image, inter-rater reliability was moderate (κ =0.671, z
- 119 = 40.6) and agreement was good ( $P_o = 78\%$ ) (**Table 3, Fig 2**).
- 120 Fig 2. Dendrogram of the respondents' lesion assessments for which a single lesion type was

#### 121 present in the image

- 122 However, when multiple lesion types were shown in an image, both inter-rater reliability (κ =0.153, z
- 123 = 10.5) and agreement ( $P_o = 29\%$ ) decreased substantially. (Table 3)
- 124 Where partial agreement was assessed, inter-rater reliability was moderate (κ =0.447, z = 25.9) and
- agreement was good ( $P_o = 73\%$ ). (Fig 3) (Table 2)
- 126 Fig 3. Dendrogram of the respondents' lesion assessments for which multiple lesion types were
- 127 present in the image
- 128

#### 129 Table 3 – Summary of inter-rater reliability and agreement results

Diagnosis of Response	Response	Lesion types	Fleiss'	Z	Percentage of agreement	
images selection formats		present in image	kappa	score	Туре	Result
Mpox & Varicella	Single choice	Single types and multiple types	0.223	10.1	Percentage of exact agreement	67.745
Мрох	Single choice	Single types	0.671	40.6	Percentage of exact agreement	78.14
Мрох	Multiple choice	Multiple types	0.447	25.9	Percentage of partial agreement	73.18
Мрох	Multiple choice	Multiple types	0.153	10.5	Percentage of exact agreement	29.04

130

## 131 Discussion

132 This study demonstrates that there are presently limitations in using clinical assessment to diagnose

133 Clade I mpox and evaluate lesion stage and treatment outcomes.

134 We found moderate accuracy, poor reliability, and moderate agreement among clinicians deciding 135 between mpox and varicella diagnosis based on lesion presentation. In settings where laboratory diagnosis is not available, or delayed, there is a risk that patients could be managed according to an 136 incorrect care pathway (e.g. provision of an incorrect antiviral). Misclassification of cases can have 137 138 implications for public health activities as varied as disease surveillance, allocation of vaccinations, 139 drug procurement, and reporting of notifiable diseases obligations. This has consequences also for 140 the evaluation of treatment effects, both in clinical practice and research, with incorrect or 141 inconsistent classification of outcomes.

142

143 We found that for classification of mpox lesion status there was moderate reliability and good 144 agreement if a single lesion type is present – although this may not be sufficient to state that there is 145 good agreement beyond chance (20, 21) – but it appears to be most challenging to obtain consistent 146 assessments when multiple lesion types are present. As lesions are unlikely to follow the same 147 evolution pattern over time, the poor reliability and agreement between clinicians when multiple 148 lesion types are present creates a substantial challenge. This includes clinical trials, which rely on a 149 single overall assessment of a patient's lesion presentation at a specific timepoint to act as an 150 indicator of a patient's overall outcome and response to treatment.

151 These findings occurred despite the self-rated confidence among the participants being high (IQR:

152 7.5-8). We found no correlation between confidence and experience defined according to the

number of patients with mpox the respondent had managed (Fig 4). Due to the sporadic and

154 widespread reporting of Clade I mpox across a large geographic area, it is possible that confidence,

and agreement among real-world clinicians, who may only occasionally manage a patient with mpox

156 or varicella, may be lower than reported in this study where we sampled a relatively expert group.

#### 157 Fig 4. Scatterplot of respondents' self-rated confidence plotted against experience (measured

158 according to the number of patients managed)

A parallel study found higher agreement and reliability among clinicians assessing Clade IIb mpox lesions. (14) This may be due to differences in lesion presentation between the two diseases, with Clade IIb lesions often being more localised and fewer than Clade I lesions. The surveys were not combined due to the significant differences in clinical presentation between the clades, and that clinical experience spanning both clades is limited to a very small number of highly-expert clinicians.

There is a continued requirement for resources (such as the WHO lesion assessment atlas) to assist clinicians and clinical triallists working in low-resource environments to improve their assessments, alongside support for improved diagnostic capacity. There is an urgent need to work to improve and find other correlates of disease progression (e.g. how much PCR status reflects ongoing infectivity).

168 Considering the lack of correlation between clinician experience and their ability to diagnose Clade I 169 Mpox, this study underscores the potential of Artificial Intelligence (AI) and Machine Learning (ML) 170 in improving Mpox diagnosis, especially in resource-constrained settings where access to doctors 171 may be limited and initial assessments are often conducted by nurses or community health workers. 172 The application of AI and ML technologies, capable of capturing and analysing images, presents a 173 significant opportunity to enhance the diagnostic accuracy of clinicians and nurses in areas lacking 174 PCR testing facilities. This advancement is particularly crucial before the availability of rapid 175 diagnostic tests. Although these technologies have demonstrated their efficacy during the pandemic, 176 specifically with the Clade IIb variant of Mpox, data on their effectiveness with Clade I remain scarce. 177 By leveraging AI, we can aim to bridge the diagnostic gap, ensuring timely and accurate detection of 178 Mpox, even in the most challenging environments, thereby improving patient outcomes and

controlling the spread of the disease more effectively. (22, 23)

## 180 Limitations

179

181 This study included a relatively low number of participants, because few clinicians worldwide have 182 current or recent experience managing patients with Clade I mpox. The response rate was also 183 challenged by difficulty identifying and reaching clinicians who work in remote areas with limited 184 internet connection. Assessments made by visual inspection of images may not be reflective of all 185 the information used to make assessments in a clinical scenario (such as patient's descriptions of 186 evolution of lesions, associated characteristics such as pain). We used reliability and agreement for 187 assessment of mpox lesions (compared to accuracy) because there is no 'gold standard' classification to which to compare. We did not provide images where there was mpox and varicella coinfection. 188

#### 189 Conclusion

190 It is difficult for experienced clinicians to distinguish clade I mpox from varicella, and to reliably
 191 assess disease stage for clade I mpox. More robust indicators and tools are required to inform

- 192 clinical, public-health, and research priorities, but these must be implementable in countries
- affected by Mpox.

## 194 Acknowledgements

195 This work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome

196 [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135]. For the purpose of Open

- 197 Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript
- 198 version arising from this submission.

### 199 References

Mitjà O, Ogoina D, Titanji BK, Galvan C, Muyembe JJ, Marks M, Orkin CM. Monkeypox.
 Lancet. 2023;401(10370):60-74.

European Centre for Disease Prevention and Control. Implications for the EU/EEA of the
 outbreak of mpox caused by Monkeypox virus clade I in the Democratic Republic of the Congo.
 2023.

 205
 3.
 World Health Organisation. Mpox (monkeypox) - Democratic Republic of the Congo. 2023.

Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A, Ihekweazu C, Zumla A.
 Human Monkeypox: Epidemiologic and Clinical Characteristics, Diagnosis, and Prevention. Infect Dis
 Clin North Am. 2019;33(4):1027-43.

209 5. Zhou Y, Chen Z. Mpox: a review of laboratory detection techniques. Arch Virol.

210 2023;168(8):221.

Masirika LM, Udaheuka JC, Schuele L, Ndishimye P, Otani S, Mbiribindi JB, et al. Novel Clade I
 genome sequences from the ongoing mpox virus outbreak of Kamituga in South Kivu province,
 Democratic Republic of Congo. Virological. 2024.

214 7. World Health Organisation. Disease Outbreak News: Monkeypox – Democratic Republic of 215 Congo. 2023.

Assessment of the Efficacy and Safety of Tecovirimat in Patients With Monkeypox Virus
 Disease (UNITY) [Internet]. clinicaltrials.gov. 2022. Available from:

218 <u>https://clinicaltrials.gov/study/NCT05597735?cond=mpox&rank=5#study-record-dates.</u>

9. Study of Tecovirimat for Human Monkeypox Virus (STOMP) [Internet]. clinicaltrials.gov.

2022. Available from: <u>https://clinicaltrials.gov/study/NCT05534984?cond=mpox&rank=6#study-</u>
 record-dates.

European Trial Into Mpox Infection (EPOXI) [Internet]. clinicaltrials.gov. 2023. Available from:
 <a href="https://clinicaltrials.gov/study/NCT06156566?cond=mpox&rank=8#study-record-dates">https://clinicaltrials.gov/study/NCT06156566?cond=mpox&rank=8#study-record-dates</a>.

11. Tecovirimat for Treatment of Monkeypox Virus [Internet]. clinicaltrials.gov. 2022. Available

from: <u>https://clinicaltrials.gov/study/NCT05559099?term=palm%20007&rank=1#study-record-</u>
 <u>dates</u>.

12. Antiviral treatment with tecovirimat for patients managed at home with mpox [Internet].ISRCTN. 2022. Available from:

https://www.isrctn.com/ISRCTN17461766?q=tecovirimat&filters=&sort=&offset=1&totalResults=3&
 page=1&pageSize=10.

medRxiv preprint doi: https://doi.org/10.1101/2024.03.21.24304658; this version posted March 24, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY 4.0 International license .

231 13. Rojek A, Dunning J, Olliaro P. Monkeypox: how will we know if the treatments work? Lancet 232 Infect Dis. 2022;22(9):1269-70.

233 Jones B, Paterson A, AlKhoury N, Bourner J, Dunning J, Olliaro P, Rojek A. Variability in 14. 234 clinical assessment of clade IIb mpox lesions. International Journal of Infectious Diseases. 235 2023;137:60-2.

236 15. Kottner J, Audige L, Brorson S, Donner A, Gajewski BJ, Hróbjartsson A, et al. Guidelines for 237 Reporting Reliability and Agreement Studies (GRRAS) were proposed. International Journal of 238 Nursing Studies. 2011;48(6):661-71.

239 16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data 240 capture (REDCap)—A metadata-driven methodology and workflow process for providing


241 translational research informatics support. Journal of Biomedical Informatics. 2009;42(2):377-81.


Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: 242 17. 243 Building an international community of software platform partners. Journal of Biomedical Informatics. 2019;95:103208. 244

245 18. Atlas of mpox lesions: a tool for clinical researchers, 28 April 2023 [Internet]. 2023. Available 246 from: https://pesquisa.bvsalud.org/portal/resource/pt/who-366569.

- 247 R Core Team. R: A language and environment for statistical computing. R Foundation for 19. 248 Statistical Computing, Vienna, Austria; 2018.
- 249 20. Altman DG. Practical Statistics for Medical Research. 1st edition ed: Chapman and Hall/CRC; 250 1990.
- 251 21. Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data.
- 252 Biometrics. 1977;33(1):159-74.
- 253 22. Nayak T, Chadaga K, Sampathila N, Mayrose H, Gokulkrishnan N, Bairy G M, et al. Deep 254 learning based detection of monkeypox virus using skin lesion images. Medicine in Novel Technology 255 and Devices. 2023;18:100243.
- 256 Chadaga K, Prabhu S, Sampathila N, Nireshwalya S, Katta SS, Tan RS, Acharya UR. Application 23. 257 of Artificial Intelligence Techniques for Monkeypox: A Systematic Review. Diagnostics (Basel).
- 258 2023;13(5).
- Supporting information 259
- 260 S1 Appendix 1 – Questionnaire
- 261 S2 Appendix 2 – Summary of question characteristics and accuracy score
- 262 S3 Appendix 3 – Full dataset

Diagnosis





Lesion type, Multiple

